Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
SLAB Silicon Laboratories Inc
NCLH Norwegian Cruise Line Holdings Ltd
SNMSF Spin Master Corp
IFBD Infobird Co Ltd
JACK Jack in the Box Inc
MVLY Mission Valley Bancorp
CLSD Clearside Biomedical Inc
GBRGU Goldenbridge Acquisition Ltd
CHMI-B Cherry Hill Mortgage Investment Corp
Go

Health Care : Biotechnology |
Company profile

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Closing Price
$0.428
Day's Change
-0.027 (-5.93%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.455
Day's Low
0.41
Volume
(Light)
Volume:
1,837,083

10-day average volume:
2,800,119
1,837,083

Company Profile

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Valuation Ratios

No valuation ratios available.

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

August 2022
Current Month
53.8K
Previous Month
50.4K
Percent of Float
0.73%
Days to Cover
1.5412 Days

Share Information

VIRI is in a share class of common stock
Float
17.4M
Shares Outstanding
18.3M
Institutions Holding Shares
21
16.13%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Gregory Scott DuncanChmn.
  • William L. Pridgen
  • Angela Walsh
  • Ralph GrosswaldSr.VP
  • R. Michael GendreauOther

Address

Insider Trading

During the most recent quarter, 26K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.